Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Rugo Offers Window Into Evolving Views of ER-Positive Disease

September 6th 2013

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

Dr. Finn on the Phase III Trial of Palbociclib for Breast Cancer

September 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Puma Begins Phase III Development of Neratinib in Breast Cancer

September 6th 2013

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

Analyzing the Nuances of Trastuzumab Therapy for HER2-Positive Breast Cancer

September 3rd 2013

Trastuzumab is the clear standard of care for firstline therapy for nearly all HER2-positive breast cancers, and the oncology community has come a long way toward understanding how best to use the drug.

Dr. Mittendorf on Cyclin E as a Target in Breast Cancer

August 29th 2013

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Did Our Founding Fathers Get It Right?

August 28th 2013

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

TNBC Studies Yield Clues for Future Directions

August 27th 2013

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer, but studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

Dr. Ho on Postmastectomy Radiation Therapy

August 22nd 2013

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.

Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

August 19th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Subgroup Analysis: Certain Patients May Benefit More From Eribulin

August 19th 2013

A subgroup analysis from a phase III study showed that certain patients may benefit more from eribulin than capecitabine, and quality of life data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.

More Genetic Screening Needed for African-American Breast Cancer Patients

August 15th 2013

One in five African-American women with breast cancer carries an abnormality in at least one gene associated with breast cancer susceptibility.

Dr. Nielsen Discusses Using a Ki67 Assay in Breast Cancer

August 13th 2013

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

CTC-Based Biomarkers Can Be Measured for Sensitivity to Novel Breast Cancer Drug

August 9th 2013

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."

Dr. Rugo on PI3K and mTOR Inhibitors for Breast Cancer

August 8th 2013

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Tamoxifen Significantly Lowers Risk of Contralateral Breast Cancer in BRCA-Positive Patients

August 6th 2013

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

Breast Cancer Heterogeneity Confounds Trial of Dual HER2-Targeted Therapy

August 5th 2013

Exploratory analyses by intrinsic subtype showed that HER2-positive breast cancer is molecularly heterogeneous with varying degrees of sensitivity to HER2-targeted therapy.

Dr. Swain on Pregnant Patients With Breast Cancer

August 5th 2013

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center and Georgetown University Medical Center, discusses pregnant patients with breast cancer.

Dr. Hershman on Adherence to Longer Hormonal Therapy

August 1st 2013

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Dr. Tripathy on Targeting HER2 in Breast Cancer

July 31st 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Dr. Albain on the 21- and 70- Gene Assays in Breast Cancer

July 26th 2013

Kathy S. Albain, MD, from the Loyola University Chicago and Cardinal Bernardin Cancer Center, discusses the difference between the 21-gene (Oncotype DX) assay and 70-gene (MammaPrint) assay in breast cancer.